COMPLIANCE INFO 1986 - 2016 - Laserfiche WebLink

Home Browse Search

State of Callfomia-Health and Welfare Agency Department of Health Services Page 5 of 7 pages RADIOACTIVE MATERIAL LICENSE License Number. 1276-39 Supplementary Sheet Amendment Number. 65 18. Records of leak test results shall be kept in units of microcuries and maintained for inspection. Records may be disposed of following Department inspection. Any leak test revealing the presence of 0.005 microcuries or more of removable radioactive material shall be reported to the Department of Health Services, Radiologic Health Branch, 601 N. 7th Street P.O. Box 942732, Sacramento, CA 94234-7320, within five days of the test. This report shall include a description of the defective source or device,the results of the test, and the corrective action taken. 19. Any licensed sealed source is exempt from such leak tests when the source contains 100 microcuries or less of beta and/or gamma emitting material or 10 microcuries or less of alpha emitting material. 20. Except for alpha sources, the periodic leak test required by Condition 15 does not apply to sealed sources that are stored and not being used. The sources excepted from this test shall be tested for leakage prior to any use or transfer to another person unless they have been leak tested within six months prior to the date of use or transfer. 21. The licensee shall conduct a physical inventory every six months to account for all sealed sources and/or devices received and possessed under the license. Records of the inventories shall be maintained for inspection, and may be disposed of following Department inspection. 22. Treatment and management of patients receiving therapeutic quantities of unsealed radioactive materials shall be in accordance with guidance contained in Chapter 4, 'Release from Hospital of Patients Containing Radioactive Material" National Council on Radiation Protection and Measurements (NCRP) Report No. 37, "Precautions in the Management of Patients Who Have Received Therapeutic Amounts of Radionuclides" (NCRP Publications, P. O. Box 30175, Washington, D. C., 20014). 23. Treatment and management of patients undergoing brachytherapy shall be in accordance with guidance contained in Chapter 5, 'Safety Precautions in Clinical Application",National Council on Radiation Protection and Measurements(NCRP)Report No. 40, Protection Against Radiation From Brachytherapy Sources(NCRP Publications, P. O. Box 30175, Washington, D.C., 20014). 24. Notwithstanding the six-month test interval requirement of Section 30275 of the California Radiation Control Regulations, medical cesium-137 sources (3M Company Models 6500 - 6507 or old Model 6D6C,and Isotope Products Model 67-800 or 67-820 series) possessed under this license may be tested for leakage and/or contamination at three-year intervals. 25. Except as otherwise specifically provided by this license, radiopharmaceuticals to be administered to humans shall be procured in prepackaged, precalibrated form from a supplier who is registered with the U. S. Food and Drug Administration, or prepared and compounded, from a prescription, in accordance with the regulations of the California Board of Pharmacy. 26. Except as otherwise specifically provided by this license, radioactive biologicals (including human serum albumin) to be administered to humans shall be procured in prepackaged, precalibrated form from a supplier who is licensed for the preparation and distribution of such products by the Division of Biologics Standards of the National Institutes of Health, or U. S. Food and Drug Administration; or prepared in accordance with the regulations of the California Board of Pharmacy. 27. Radioactive materials prepared, processed, or modified by the licensee shall not be administered to humans except as specifically authorized by this license.